Course director: Dr. András Inotai

4-day course in health policy (2 credits)

 

Each day consists of 6 x 45-minute classes

 

 

Day 1

Principles of health economics, elements of health technology assessment, economic evaluations

Zoltán Kaló/ András Inotai

Day 2

Development of cost-effectiveness and budget impact models to support pharmaceutical policy decisions

Balázs Nagy

Day 3

Principles and implementation of value frameworks and Multicriteria Decision Analyses to support policy decisions

Zoltán Kaló 

Day 4

Theory and practice of managed entry decisions

András Inotai

Technical requirements: participants should bring their own computer

 

Evaluation of prior PhD courses by participants and Action plan (in HU):

EVIDENCE-BASED PHARMACEUTICAL POLICY DECISION-MAKING IN LOWER-INCOME EUROPEAN COUNTRIES Evaluation

 

HEALTH ECONOMICS COURSE

organised by the

Center for Health Technology Assessment,

SEMMELWEIS UNIVERSITY, Budapest

COURSE DATE: 05–08 April 2027, 9 AM-4 PM

Applied health economics: Evidence-based pharmaceutical policy decision-making in lower-income European countries

For Whom?

For representatives of health care payers, HTA agencies, academic research teams and market access teams of the pharmaceutical industry or consultant companies who are involved or interested in-, or influenced by evidence-based policy decisions in countries with economic constraints.

Why?

Evidence-based decision-making is especially important in less affluent countries with more limited health care resources and generally poorer overall health status, as the opportunity cost of suboptimal pharmaceutical policy decisions is higher in these countries.

Brief description

The course – in parallel with providing basic insights into the theory of economic evaluation, modeling, managed entry agreements and multi criteria decision analysis (MCDA) – will primarily be based on case studies. Participants will develop an economic model and use it for designing managed entry agreement scenarios and understanding their influence on the cost-effectiveness and the budget impact of pharmaceuticals at their market entry. As the traditional economic value frameworks may be too narrow to capture patient-centric and societal value elements, participants will develop an extended value framework and evaluate policy scenarios by MCDA.

Participation will be face-to-face (seating is limited).

Lecturers:  

  Assoc. Prof. András Inotai     Prof. Zoltán Kaló                  Assoc. Prof. Balázs Nagy                                                                                                                                          

For more information, please download our detailed brochures from here:

Applied_Health Economics_Flyer_Q2_2027

Registration
Please note: participation is free of charge for faculty members (HTA Center) and PhD students currently studying at Semmelweis University.
 
In order to register for our winter courses:

Important: After sending your registration form by email, please wait for receiving your invoice first. Only after you received your invoice transfer the registration fee.

Thank you!